$CLLS $ALCLS 
$ALLO $PFE
https://t.co/GoFPPhzrRO
Proprietary #allogeneic CAR T-cell programs on track in Phase 1 dose escalation trials; AMELI-01 in r/r AML patients, BALLI-01 in r/r B-ALL patients and MELANI-01 in r/r MM patients